NCT05938296 - OHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

January 1, 2026

Conditions

Solid Tumor

Interventions

DRUG

BS006 Injection

BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.

Trial Locations (2)

32806

RECRUITING

Orlando Health Cancer Institute, Orlando

48201

RECRUITING

Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit